BIOTYPE and APIS Partner to Commercialize Two Cancer-Related Molecular Tests
The agreement covers an ESR1 mutation detection kit for metastatic breast cancer and a DPYD genotyping kit for assessing chemotherapy toxicity risk.
Category: Breast
Breast
Latest
Breast
Latest
Study Highlights Need for Family History in BRCA Test Interpretation
A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.
Breast
Latest
Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer, Study Shows
Researchers at Vanderbilt-Ingram Cancer Center report that RNA sequencing of blood samples can predict immunotherapy response in high-risk breast cancer patients.
New AI Test Estimates Individualized Chemotherapy Benefit in Breast Cancer Patients
Using causal artificial intelligence and digital pathology, the test moves beyond population-level averages to predict patient-specific chemotherapy outcomes.
Read More
Ultrasensitive ctDNA Test Outperforms Standard Metrics in Predicting Breast Cancer Outcomes After Neoadjuvant Therapy
A study found that circulating tumor DNA testing detected residual disease signals missed by conventional prognostic measures in patients with breast cancer.
Read More
Ibex Medical Analytics Launches Next-Generation AI Pathology Platform
Ibex Medical Analytics has launched Ibex 4, an AI-powered pathology platform with expanded end-to-end breast cancer diagnostic workflows, zero-click IHC tools, and enhanced lab integration capabilities for increased efficiency.
Read More
Blood Test May Help Guide Breast Cancer Treatment Decisions in Women 70 and Older
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
Read More
Study Finds Multi-Omic Breast Cancer Test Predicts Radiation Therapy Benefit
Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More
Researchers Identify Four New Markers for Detecting Aggressive Breast Cancer Cells in Blood
Researchers at Baylor College of Medicine have identified four new protein markers that improve detection of triple-negative breast cancer cells in blood, potentially enhancing the accuracy of liquid biopsy tests, according to a recent study.
Read More
ctDNA Testing May Better Predict Breast Cancer Recurrence Than Current Standard
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
PreciseDx Presents Validation Data for AI Breast Cancer Recurrence Test
Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Read More
CTC Counts Show Value in Guiding Metastatic Breast Cancer Treatment Decisions
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More
Roche Gains FDA Approval for Expanded HER2 Diagnostic Test Indications
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
Read More
Test Validated to Predict Recurrence Risk and Radiation Therapy Benefit in Breast Cancer
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read More
Medicare Covers Ultrasensitive MRD Test for Breast Cancer Surveillance
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read More
YD Bio Expands US Access to Blood Test for Post‑Treatment Breast Cancer Monitoring
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Read More
Biodesix Expands Bio-Rad Partnership for Droplet Digital PCR Assay Development
The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.
Read More
Blood Test Achieves 85% Accuracy in Predicting Breast Cancer Immunotherapy Response
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More